Pharsight

Allergan patents expiration

1. Acular Ls patents expiration

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(3 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(9 months from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(3 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating ocular pain; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain and/or enhancing ocular comfort; A met...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage

ACULAR LS family patents

Family Patents

2. Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7842714 ALLERGAN Ketorolac tromethamine compositions for treating ocular pain
Aug, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Aug, 2024

(5 months from now)

US8512717 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(4 years from now)

US9192571 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(4 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents

3. Alphagan P patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687443

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US9295641

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6562873

(Pediatric)

ALLERGAN Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(2 years ago)

US6627210

(Pediatric)

ALLERGAN Compositions containing α-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6673337

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6641834

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(5 months ago)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(6 days from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's drug patent expiration?
More Information on Dosage

ALPHAGAN P family patents

Family Patents

4. Avycaz patents expiration

AVYCAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(1 year, 10 months from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(7 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(2 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
New Patient Population (NPP) Dec 20, 2025
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 2024-02-26

Market Authorisation Date: 25 February, 2015

Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

5. Byvalson patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ALLERGAN Compositions comprising nebivolol
Aug, 2026

(2 years from now)

US7838552 ALLERGAN Compositions comprising nebivolol
Oct, 2027

(3 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's drug patent expiration?
More Information on Dosage

BYVALSON family patents

Family Patents

6. Canasa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217083 ALLERGAN Mesalamine suppository
Jun, 2028

(4 years from now)

US8436051 ALLERGAN Mesalamine suppository
Jun, 2028

(4 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 05 January, 2001

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

How can I launch a generic of CANASA before it's drug patent expiration?
More Information on Dosage

CANASA family patents

Family Patents

7. Dalvance patents expiration

DALVANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(3 months ago)

US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(3 months ago)

US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(3 months ago)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 2023-05-24

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DALVANCE family patents

Family Patents

8. Fetzima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(1 year, 10 months from now)

US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

9. Gelnique patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259388 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(5 years from now)

US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(7 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence wi...

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage

GELNIQUE family patents

Family Patents

10. Gelnique 3% patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801 ALLERGAN Formulations for transdermal or transmucosal application
Jun, 2022

(1 year, 8 months ago)

Drugs and Companies using OXYBUTYNIN ingredient

Market Authorisation Date: 07 December, 2011

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

More Information on Dosage

GELNIQUE 3% family patents

Family Patents

11. Lastacaft patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine
Mar, 2027

(3 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine
Dec, 2027

(3 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LASTACAFT before it's drug patent expiration?
More Information on Dosage

LASTACAFT family patents

Family Patents

12. Latisse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US8986715 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US8632760 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(1 year, 1 month ago)

US8263054 ALLERGAN Method of enhancing hair growth
Jan, 2023

(1 year, 1 month ago)

US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(2 months from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of increasing eyelash growth; Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth including length, thickness, darknes...

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage

LATISSE family patents

Family Patents

13. Lexapro patents expiration

LEXAPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(1 year, 6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7420069 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(1 year, 6 months ago)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(1 year, 12 days ago)

US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(1 year, 12 days ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 12, 2026

Drugs and Companies using ESCITALOPRAM OXALATE ingredient

Market Authorisation Date: 14 August, 2002

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LEXAPRO before it's drug patent expiration?
More Information on Dosage

LEXAPRO family patents

Family Patents

14. Linzess patents expiration

LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(27 days ago)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(27 days ago)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(27 days ago)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(27 days ago)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(27 days ago)

US8933030 ALLERGAN Treatments for gastrointestinal disorders
Feb, 2031

(6 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(7 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(7 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
Oct, 2031

(7 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide
Oct, 2031

(7 years from now)

US9708371 ALLERGAN Treatments for gastrointestinal disorders
Aug, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jun 12, 2026

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constip...

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage

LINZESS family patents

Family Patents

15. Namenda Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(5 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(5 years from now)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage

NAMENDA XR family patents

Family Patents

16. Namzaric patents expiration

NAMZARIC's oppositions filed in EPO
NAMZARIC Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338486 ALLERGAN Methods for the treatment of CNS-related conditions
Nov, 2025

(1 year, 8 months from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 8 months from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 8 months from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 8 months from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 8 months from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 8 months from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 8 months from now)

US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 8 months from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 8 months from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 8 months from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions
May, 2026

(2 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(2 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(5 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(5 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Dec, 2029

(5 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage

NAMZARIC family patents

Family Patents

17. Ozurdex patents expiration

OZURDEX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8506987 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US10076526 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US8034370 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US9192511 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US10702539 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US8034366 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(1 year, 1 month ago)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants
Nov, 2023

(3 months ago)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of macular edema; Treatment of uveitis; Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo...

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

OZURDEX family patents

Family Patents

18. Saphris patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7741358 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(2 years from now)

US8022228 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022228

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(2 years from now)

US7741358

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(2 years from now)

Drugs and Companies using ASENAPINE MALEATE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of mani...

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage

SAPHRIS family patents

Family Patents

19. Savella patents expiration

Can you believe SAVELLA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6602911 ALLERGAN Methods of treating fibromyalgia
Jan, 2023

(1 year, 1 month ago)

US7994220 ALLERGAN Milnacipran for the long-term treatment of fibromyalgia syndrome
Sep, 2029

(5 years from now)

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 January, 2009

Treatment: Management of fibromyalgia (fm); Management of fibromyalgia

Dosage: TABLET;ORAL

How can I launch a generic of SAVELLA before it's drug patent expiration?
More Information on Dosage

SAVELLA family patents

Family Patents

20. Teflaro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(1 year, 10 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629861 ALLERGAN Compositions and methods for treating bacterial infections using ceftaroline
Sep, 2030

(6 years from now)

US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections
Feb, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Sep 13, 2022

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Market Authorisation Date: 29 October, 2010

Treatment: Method of treating bacterial infections; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of TEFLARO before it's drug patent expiration?
More Information on Dosage

TEFLARO family patents

Family Patents

21. Viibryd patents expiration

VIIBRYD Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(1 year, 8 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(1 year, 8 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236804 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Jun, 2022

(1 year, 8 months ago)

US8193195 ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(1 year, 8 months ago)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Dec, 2022

(1 year, 2 months ago)

US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(1 year, 2 months ago)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(1 year, 2 months ago)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Dec, 2022

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jan 31, 2023
Pediatric Exclusivity (PED) Jul 31, 2023

Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 January, 2011

Treatment: Treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of VIIBRYD before it's drug patent expiration?
More Information on Dosage

VIIBRYD family patents

Family Patents